lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma
Published 1 year ago • 1.2K plays • Length 5:19Download video MP4
Download video MP3
Similar videos
-
2:06
lenvatinib plus pembro for arcc - update on the clear study
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
7:37
lenvatinib as up-front therapy for unresectable hcc
-
5:17
leap-002: lenvatinib plus pembrolizumab for first-line advanced hcc?
-
1:43
treatment for advanced-stage hcc
-
2:56
dr. finn on role of lenvatinib in hcc treatment paradigm
-
17:55
hepatocellular carcinoma: medical treatment
-
8:55
implication of upfront lenvatinib in hcc
-
1:24
phase iii findings for lenvatinib in hcc
-
8:28
lenvatinib in advanced dtc
-
6:05
leap-004: lenvatinib pembrolizumab for patients with advanced melanoma and confirmed progressi...
-
3:28
lenvatinib for hepatocellular carcinoma
-
1:33
adverse events inform treatment decisions in hcc for frontline lenvatinib versus sorafenib
-
8:28
debate: optimal first-line therapy in unresectable hcc? - mki followed by immunotherapy
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
4:05
lenvatinib increases progression free survival with everolimus in metastatic renal cell carcinoma
-
4:03
real-world outcomes of patients with hcc treated with lenvatinib vs. atezolizumab plus bevacizumab
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
6:08
imbrave150 trial: combination therapy in advanced hcc